GlassScriptPhysician profile
Erin Nicole Soloway
NPI 1114355211
$6,201.55
in general payments reported to CMS, 2019-2025
55 companies · $5,418 in 2025
The $5,418 reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $235 · 2023: $189 · 2024: $359 · 2025: $5,418.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,093 · Long Term Medical Supply Or Device Loan: $698 · Education: $176.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,092.54 |
| Long Term Medical Supply Or Device Loan | $697.90 |
| Education | $175.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $993.03 | 2025 | |
| Pfizer INC. | $643.68 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $634.25 | 2022-2025 | Imfinzi, Fasenra, Enhertu |
| Incyte Corporation | $318.93 | 2025 | Jakafi, Monjuvi, Niktimvo |
| Janssen Biotech, INC. | $310.60 | 2025 | Talvey, Tecvayli, Darzalex |
| Daiichi Sankyo INC. | $245.96 | 2025 | Enhertu, Injectafer, Datroway |
| Beone Medicines USA, INC. | $216.37 | 2025 | Brukinsa, Tevimbra |
| Bayer Healthcare Pharmaceuticals INC. | $207.17 | 2024-2025 | |
| Celgene Corporation | $198.34 | 2022-2025 | Reblozyl, Opdualag |
| Merck Sharp & Dohme LLC | $183.91 | 2025 | Keytruda, Lynparza, Keytruda Qlex |
| Gilead Sciences, INC. | $131.55 | 2025 | Trodelvy |
| Abbvie INC. | $130.33 | 2022-2024 | |
| Jazz Pharmaceuticals INC. | $106.45 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $102.71 | 2025 | Ninlaro, Fruzaqla |
| Puma Biotechnology, INC. | $102.68 | 2023-2025 |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $96.00 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $89.45 | 2025 | Onivyde |
| Boehringer Ingelheim Pharmaceuticals, INC. | $85.29 | 2025 | |
| Pharmacosmos Therapeutics INC. | $81.68 | 2025 | Monoferric |
| Sobi, INC | $80.13 | 2025 | |
| Lilly USA, LLC | $76.52 | 2025 | Verzenio, Jaypirca |
| Glaxosmithkline, LLC. | $67.58 | 2025 | Ojjaara, Zejula, Jemperli |
| Eisai INC. | $65.42 | 2025 | |
| Tersera Therapeutics LLC | $62.40 | 2024-2025 | Zoladex, Quzyttir |
| Beigene USA, INC. | $56.77 | 2025 | Brukinsa |
| Genzyme Corporation | $53.30 | 2025 | |
| Array Biopharma INC | $52.60 | 2025 | Xalkori, Mektovi, Braftovi |
| Tempus Ai, INC | $52.05 | 2025 | Xt Cdx |
| Rigel Pharmaceuticals, INC. | $47.27 | 2024 | Tavalisse, Rezlidhia |
| Genentech USA, INC. | $45.47 | 2025 | Itovebi, Venclexta, Polivy |
| Caris Mpi, INC. | $45.39 | 2025 | Mi Cancer Seek |
| Alexion Pharmaceuticals, INC. | $43.11 | 2025 | Ultomiris |
| Janssen Scientific Affairs, LLC | $41.25 | 2025 | Carvykti, Darzalex, Tecvayli |
| Dendreon Pharmaceuticals LLC | $38.32 | 2025 | Provenge |
| Deciphera Pharmaceuticals INC. | $37.51 | 2024-2025 | Qinlock, Tgct, Romvimza |
| Progenics Pharmaceuticals, INC. | $37.21 | 2024-2025 | |
| Adc Therapeutics America, INC. | $35.13 | 2025 | |
| Amneal Pharmaceuticals LLC | $28.90 | 2025 | Alymsys |
| Stemline Therapeutics INC. | $26.58 | 2024 | Orserdu |
| Regeneron Healthcare Solutions, INC. | $26.21 | 2024 | Libtayo |
| Kyowa Kirin, INC. | $24.39 | 2025 | |
| Genmab U.S., INC. | $24.17 | 2025 | Epkinly |
| Agios Pharmaceuticals, INC. | $22.38 | 2025 | Pyrukynd |
| Servier Pharmaceuticals LLC | $22.35 | 2025 | |
| Tolmar, INC. | $21.10 | 2025 | Eligard |
| Geron Corporation | $21.07 | 2025 | Rytelo |
| Sumitomo Pharma America, INC. | $20.54 | 2025 | Orgovyx |
| Spectrum Pharmaceuticals INC. | $20.28 | 2025 | Rolvedon |
| Aveo Pharmaceuticals, INC. | $20.09 | 2025 | |
| Pharmaand Gmbh | $19.22 | 2025 | Rubraca |
| Recordati_rare_diseases_inc. | $18.78 | 2025 | Enjaymo |
| Legend Biotech USA INC. | $18.53 | 2025 | Carvykti |
| Astellas Pharma US INC | $18.35 | 2025 | Xtandi |
| Karyopharm Therapeutics INC. | $16.54 | 2024 | Xpovio |
| Apellis Pharmaceuticals, INC. | $16.26 | 2025 | Empaveli |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Soloway listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.